| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 5553- | BBM, | A review on berbamine–a potential anticancer drug |
| - | Review, | Var, | NA |
| 1398- | BBR, | Berberine inhibits the progression of renal cell carcinoma cells by regulating reactive oxygen species generation and inducing DNA damage |
| - | in-vitro, | Kidney, | NA |
| 1394- | BBR, | DL, | Synergistic Inhibitory Effect of Berberine and d-Limonene on Human Gastric Carcinoma Cell Line MGC803 |
| - | in-vitro, | GC, | MGC803 |
| 1393- | BBR, | EPI, | Berberine promotes antiproliferative effects of epirubicin in T24 bladder cancer cells by enhancing apoptosis and cell cycle arrest |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 1390- | BBR, | Rad, | Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 |
| 1374- | BBR, | PDT, | Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells |
| - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | HK-2 |
| 1378- | BBR, | Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway |
| - | in-vitro, | Lung, | NA |
| 1382- | BBR, | Berberine increases the expression of cytokines and proteins linked to apoptosis in human melanoma cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 |
| 1402- | BBR, | Berberine-induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction |
| - | in-vitro, | GBM, | T98G |
| 1404- | BBR, | Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation |
| - | in-vitro, | Pca, | PC3 |
| 2689- | BBR, | Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells |
| - | in-vitro, | Nor, | PC12 | - | in-vitro, | AD, | NA | - | in-vitro, | Stroke, | NA |
| 2700- | BBR, | Cell-specific pattern of berberine pleiotropic effects on different human cell lines |
| - | in-vitro, | GBM, | U343 | - | in-vitro, | GBM, | MIA PaCa-2 | - | in-vitro, | Nor, | HDFa |
| 2691- | BBR, | Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells |
| - | in-vitro, | Oral, | KB |
| 2674- | BBR, | Berberine: A novel therapeutic strategy for cancer |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 2681- | BBR, | PDT, | Berberine-photodynamic induced apoptosis by activating endoplasmic reticulum stress-autophagy pathway involving CHOP in human malignant melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 2686- | BBR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Nor, | NA |
| 1030- | BBR, | Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5 |
| - | in-vitro, | Lung, | H460 |
| 5179- | BBR, | Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy |
| - | Review, | Var, | NA |
| 5178- | BBR, | Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 5177- | BBR, | Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway |
| - | in-vitro, | Oral, | HMC3 |
| 5176- | BBR, | Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice |
| - | vitro+vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | LoVo |
| 5633- | BCA, | Mechanisms Behind the Pharmacological Application of Biochanin-A: A review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5636- | BCA, | Biochanin A Induces S Phase Arrest and Apoptosis in Lung Cancer Cells |
| - | vitro+vivo, | Lung, | A549 |
| 5639- | BCA, | Biochanin A Induces Apoptosis in MCF-7 Breast Cancer Cells through Mitochondrial Pathway and Pi3K/AKT Inhibition |
| - | in-vitro, | BC, | NA |
| 5592- | BetA, | Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa |
| 5591- | BetA, | Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment |
| - | Review, | BC, | NA |
| 2722- | BetA, | Betulinic Acid for Cancer Treatment and Prevention |
| - | Review, | Var, | NA |
| 2718- | BetA, | The anti-cancer effect of betulinic acid in u937 human leukemia cells is mediated through ROS-dependent cell cycle arrest and apoptosis |
| - | in-vitro, | AML, | U937 |
| 2719- | BetA, | Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 2734- | BetA, | Betulinic Acid Modulates the Expression of HSPA and Activates Apoptosis in Two Cell Lines of Human Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 2729- | BetA, | Betulinic acid in the treatment of tumour diseases: Application and research progress |
| - | Review, | Var, | NA |
| 2717- | BetA, | Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma |
| - | in-vitro, | Melanoma, | U266 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | RPMI-8226 |
| 2733- | BetA, | Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling |
| - | in-vitro, | Oral, | KB | - | in-vivo, | NA, | NA |
| 2755- | BetA, | Cytotoxic Potential of Betulinic Acid Fatty Esters and Their Liposomal Formulations: Targeting Breast, Colon, and Lung Cancer Cell Lines |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | H460 |
| 2744- | BetA, | Betulin and betulinic acid: triterpenoids derivatives with a powerful biological potential |
| - | Review, | Var, | NA |
| 2752- | BetA, | Betulinic acid: a natural product with anticancer activity |
| - | Review, | Var, | NA |
| 5720- | BF, | Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway |
| - | in-vitro, | NSCLC, | NA |
| 5726- | BF, | Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species-mediated apoptosis by targeting the electron transport chain |
| - | Review, | neuroblastoma, | SK-N-BE |
| 5725- | BF, | TMZ, | Bufalin Induces Apoptosis and Improves the Sensitivity of Human Glioma Stem-Like Cells to Temozolamide |
| - | in-vitro, | GBM, | NA |
| 5724- | BF, | A Novel Bufalin Derivative Exhibited Stronger Apoptosis-Inducing Effect than Bufalin in A549 Lung Cancer Cells and Lower Acute Toxicity in Mice |
| - | vitro+vivo, | Lung, | A549 |
| 5722- | BF, | Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 5728- | BF, | Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action |
| - | in-vitro, | Lung, | A549 |
| 5686- | BJ, | BRU, | A review of Brucea javanica: metabolites, pharmacology and clinical application |
| - | Review, | Var, | NA |
| 5688- | BJ, | Brucea Javanica Oil Emulsion Injection inhibits proliferation of pancreatic cancer via regulating apoptosis-related genes |
| - | vitro+vivo, | PC, | MIA PaCa-2 |
| 5692- | BJ, | Seed oil of Brucea javanica induces apoptosis through the PI3K/Akt signaling pathway in acute lymphocytic leukemia Jurkat cells |
| - | vitro+vivo, | AML, | NA |
| 5483- | BM, | The Role of Bacopa monnieri in Alzheimer’s Disease: Mechanisms and Potential Clinical Use—A Review |
| - | Review, | AD, | NA |
| 5685- | BML, | The Therapeutic Effects of Bromelain against Colorectal Cancer: A Systematic Review |
| - | Review, | CRC, | NA |
| 5683- | BML, | Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway |
| - | in-vitro, | NA, | NA |
| 5680- | BML, | Anticancer properties of bromelain: State-of-the-art and recent trends |
| - | Review, | Var, | NA |
| 5678- | BML, | Bromelain inhibits the ability of colorectal cancer cells to proliferate via activation of ROS production and autophagy |
| - | in-vivo, | CRC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid